Suchergebnisse - "rucaparib"

PubPharm (226)

1

Effect of MYC and PARP Inhibitors in Ovarian Cancer Using an In Vitro Model

enthalten in: Anticancer research | 2024

von Morea, A. | Saravi, S. | Sisu, C. | +4

2

enthalten in: Aktuelle Urologie | 2024

3

enthalten in: Aktuelle Urologie | 2024

4

Safety and efficacy of Rucaparib in the treatment of ovarian cancer and patients with BRCA mutation : a systematic review and meta-analysis of phase III randomized clinical trials

enthalten in: Expert review of anticancer therapy | 2024

von Mustafa, M. | Abushanab, A. | Mousa, M. | +4

5

The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Brown, T. | Yablonovitch, A. | Till, J. | +11

CommentIn: Clin Cancer Res. 2023 Dec 15;29(24):5005-5007. - PMID 37787975

6

Rucaparib inhibits lung adenocarcinoma cell proliferation and migration via the SHCBP1/CDK1 pathway

enthalten in: The FEBS journal | 2023

von Dai, Y. | Hu, C. | Zhou, H. | +7

7

Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration : Final Results from the Phase 2 TRITON2 Study

enthalten in: European urology | 2023

von Abida, W. | Campbell, D. | Patnaik, A. | +27

8

A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Pook, D. | Geynisman, D. | Carles, J. | +18

9

Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial

enthalten in: Gynecologic oncology | 2023

von Peipert, J. | Goble, S. | Isaacson, J. | +5

10

A real-world disproportionality analysis of Rucaparib : Post-marketing Pharmacovigilance Data

enthalten in: BMC cancer | 2023

von Zhang, Q. | Ding, Y. | Shu, Y. | +1

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[23]